AbbVie acquires Cerevel Therapeutics for $8.7bn
AbbVie will bolster its neuroscience portfolio by adding complementary assets from Cerevel's pipeline.
02 August 2024
02 August 2024
AbbVie will bolster its neuroscience portfolio by adding complementary assets from Cerevel's pipeline.
Patients treated with Leqembi over three years have demonstrated a slowing of Alzheimer’s disease progression.
Ralph Carmona was diagnosed with mild cognitive impairment (MCI) due to Alzheimer’s in 2014.
HilleVax’s norovirus vaccine HIL-214 failed to meet key endpoints in its Phase IIb trial in infants, prompting the company to let go of 41 employees.
The expanded facility will cover 36,000m² at its existing BioCampus site and become operational in 2029.
The acquisition is expected to conclude in Q3 this year and will see Otsuka adding Jnana’s Phase I/II phenylketonuria therapy to its rare disease portfolio.
Rejuvenate and SAS will create a tool to simplify the drug development process, used to repurpose drugs for age-related diseases.
There are currently no approved vaccines for a shigella infection, which leads to an intestinal condition called shigellosis.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.